Copyright Reports & Markets. All rights reserved.

Global Antisense Oligonucleotide Therapies Market Growth (Status and Outlook) 2021-2026

Request for Sample of this report
Buy now

1 Scope of the Report

  • 1.1 Market Introduction
  • 1.2 Years Considered
  • 1.3 Research Objectives
  • 1.4 Market Research Methodology
  • 1.5 Research Process and Data Source
  • 1.6 Economic Indicators
  • 1.7 Currency Considered

2 Executive Summary

  • 2.1 World Market Overview
    • 2.1.1 Global Antisense Oligonucleotide Therapies Market Size 2016-2026
    • 2.1.2 Antisense Oligonucleotide Therapies Market Size CAGR by Region 2020 VS 2021 VS 2026
  • 2.2 Antisense Oligonucleotide Therapies Segment by Type
    • 2.2.1 Without GalNAc-conjugated
    • 2.2.2 Without GalNAc-conjugated
  • 2.3 Antisense Oligonucleotide Therapies Market Size by Type
    • 2.3.1 Global Antisense Oligonucleotide Therapies Market Size CAGR by Type
    • 2.3.2 Global Antisense Oligonucleotide Therapies Market Size Market Share by Type (2016-2021)
  • 2.4 Antisense Oligonucleotide Therapies Segment by Application
    • 2.4.1 Genetic Disease
    • 2.4.2 Cancer
    • 2.4.3 Cardiovascular Diseases
    • 2.4.4 Other
  • 2.5 Antisense Oligonucleotide Therapies Market Size by Application
    • 2.5.1 Global Antisense Oligonucleotide Therapies Market Size CAGR by Application
    • 2.5.2 Global Antisense Oligonucleotide Therapies Market Size Market Share by Application (2016-2021)

3 Antisense Oligonucleotide Therapies Market Size by Players

  • 3.1 Antisense Oligonucleotide Therapies Market Size Market Share by Players
    • 3.1.1 Global Antisense Oligonucleotide Therapies Revenue by Players (2019-2021E)
    • 3.1.2 Global Antisense Oligonucleotide Therapies Revenue Market Share by Players (2019-2021E)
  • 3.2 Global Antisense Oligonucleotide Therapies Key Players Head office and Products Offered
  • 3.3 Market Concentration Rate Analysis
    • 3.3.1 Competition Landscape Analysis
    • 3.3.2 Concentration Ratio (CR3, CR5 and CR10) (2019-2021E)
  • 3.4 New Products and Potential Entrants
  • 3.5 Mergers & Acquisitions, Expansion

4 Antisense Oligonucleotide Therapies by Regions

  • 4.1 Antisense Oligonucleotide Therapies Market Size by Regions (2016-2021)
  • 4.2 Americas Antisense Oligonucleotide Therapies Market Size Growth (2016-2021)
  • 4.3 APAC Antisense Oligonucleotide Therapies Market Size Growth (2016-2021)
  • 4.4 Europe Antisense Oligonucleotide Therapies Market Size Growth (2016-2021)
  • 4.5 Middle East & Africa Antisense Oligonucleotide Therapies Market Size Growth (2016-2021)

5 Americas

  • 5.1 Americas Antisense Oligonucleotide Therapies Market Size by Country (2016-2021)
  • 5.2 Americas Antisense Oligonucleotide Therapies Market Size by Type (2016-2021)
  • 5.3 Americas Antisense Oligonucleotide Therapies Market Size by Application (2016-2021)
  • 5.4 United States
  • 5.5 Canada
  • 5.6 Mexico
  • 5.7 Brazil

6 APAC

  • 6.1 APAC Antisense Oligonucleotide Therapies Market Size by Region (2016-2021)
  • 6.2 APAC Antisense Oligonucleotide Therapies Market Size by Type (2016-2021)
  • 6.3 APAC Antisense Oligonucleotide Therapies Market Size by Application (2016-2021)
  • 6.4 China
  • 6.5 Japan
  • 6.6 Korea
  • 6.7 Southeast Asia
  • 6.8 India
  • 6.9 Australia

7 Europe

  • 7.1 Europe Antisense Oligonucleotide Therapies by Country (2016-2021)
  • 7.2 Europe Antisense Oligonucleotide Therapies Market Size by Type (2016-2021)
  • 7.3 Europe Antisense Oligonucleotide Therapies Market Size by Application (2016-2021)
  • 7.4 Germany
  • 7.5 France
  • 7.6 UK
  • 7.7 Italy
  • 7.8 Russia

8 Middle East & Africa

  • 8.1 Middle East & Africa Antisense Oligonucleotide Therapies by Region (2016-2021)
  • 8.2 Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Type (2016-2021)
  • 8.3 Middle East & Africa Antisense Oligonucleotide Therapies Market Size by Application (2016-2021)
  • 8.4 Egypt
  • 8.5 South Africa
  • 8.6 Israel
  • 8.7 Turkey
  • 8.8 GCC Countries

9 Market Drivers, Challenges and Trends

  • 9.1 Market Drivers and Impact
    • 9.1.1 Growing Demand from Key Regions
    • 9.1.2 Growing Demand from Key Applications and Potential Industries
  • 9.2 Market Challenges and Impact
  • 9.3 Market Trends

10 Global Antisense Oligonucleotide Therapies Market Forecast

  • 10.1 Global Antisense Oligonucleotide Therapies Forecast by Regions (2021-2026)
    • 10.1.1 Global Antisense Oligonucleotide Therapies Forecast by Regions (2021-2026)
    • 10.1.2 Americas Antisense Oligonucleotide Therapies Forecast
    • 10.1.3 APAC Antisense Oligonucleotide Therapies Forecast
    • 10.1.4 Europe Antisense Oligonucleotide Therapies Forecast
    • 10.1.5 Middle East & Africa Antisense Oligonucleotide Therapies Forecast
  • 10.2 Americas Antisense Oligonucleotide Therapies Forecast by Countries (2021-2026)
    • 10.2.1 United States Antisense Oligonucleotide Therapies Market Forecast
    • 10.2.2 Canada Antisense Oligonucleotide Therapies Market Forecast
    • 10.2.3 Mexico Antisense Oligonucleotide Therapies Market Forecast
    • 10.2.4 Brazil Antisense Oligonucleotide Therapies Market Forecast
  • 10.3 APAC Antisense Oligonucleotide Therapies Forecast by Region (2021-2026)
    • 10.3.1 China Antisense Oligonucleotide Therapies Market Forecast
    • 10.3.2 Japan Antisense Oligonucleotide Therapies Market Forecast
    • 10.3.3 Korea Antisense Oligonucleotide Therapies Market Forecast
    • 10.3.4 Southeast Asia Antisense Oligonucleotide Therapies Market Forecast
    • 10.3.5 India Antisense Oligonucleotide Therapies Market Forecast
    • 10.3.6 Australia Antisense Oligonucleotide Therapies Market Forecast
  • 10.4 Europe Antisense Oligonucleotide Therapies Forecast by Country (2021-2026)
    • 10.4.1 Germany Antisense Oligonucleotide Therapies Market Forecast
    • 10.4.2 France Antisense Oligonucleotide Therapies Market Forecast
    • 10.4.3 UK Antisense Oligonucleotide Therapies Market Forecast
    • 10.4.4 Italy Antisense Oligonucleotide Therapies Market Forecast
    • 10.4.5 Russia Antisense Oligonucleotide Therapies Market Forecast
  • 10.5 Middle East & Africa Antisense Oligonucleotide Therapies Forecast by Region (2021-2026)
    • 10.5.1 Egypt Antisense Oligonucleotide Therapies Market Forecast
    • 10.5.2 South Africa Antisense Oligonucleotide Therapies Market Forecast
    • 10.5.3 Israel Antisense Oligonucleotide Therapies Market Forecast
    • 10.5.4 Turkey Antisense Oligonucleotide Therapies Market Forecast
    • 10.5.5 GCC Countries Antisense Oligonucleotide Therapies Market Forecast
  • 10.6 Global Antisense Oligonucleotide Therapies Forecast by Type (2021-2026)
  • 10.7 Global Antisense Oligonucleotide Therapies Forecast by Application (2021-2026)

11 Key Players Analysis

  • 11.1 Ionis Pharmaceuticals
    • 11.1.1 Ionis Pharmaceuticals Company Information
    • 11.1.2 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Product Offered
    • 11.1.3 Ionis Pharmaceuticals Antisense Oligonucleotide Therapies Revenue, Gross Margin and Market Share (2019-2021)
    • 11.1.4 Ionis Pharmaceuticals Main Business Overview
    • 11.1.5 Ionis Pharmaceuticals Latest Developments
  • 11.2 Sarepta Therapeutics
    • 11.2.1 Sarepta Therapeutics Company Information
    • 11.2.2 Sarepta Therapeutics Antisense Oligonucleotide Therapies Product Offered
    • 11.2.3 Sarepta Therapeutics Antisense Oligonucleotide Therapies Revenue, Gross Margin and Market Share (2019-2021)
    • 11.2.4 Sarepta Therapeutics Main Business Overview
    • 11.2.5 Sarepta Therapeutics Latest Developments
  • 11.3 Nippon Shinyaku
    • 11.3.1 Nippon Shinyaku Company Information
    • 11.3.2 Nippon Shinyaku Antisense Oligonucleotide Therapies Product Offered
    • 11.3.3 Nippon Shinyaku Antisense Oligonucleotide Therapies Revenue, Gross Margin and Market Share (2019-2021)
    • 11.3.4 Nippon Shinyaku Main Business Overview
    • 11.3.5 Nippon Shinyaku Latest Developments

12 Research Findings and Conclusion

According to this latest study, the 2021 growth of Antisense Oligonucleotide Therapies will have significant change from previous year. By the most conservative estimates of global Antisense Oligonucleotide Therapies market size (most likely outcome) will be a year-over-year revenue growth rate of % in 2021, from US$ million in 2020. Over the next five years the Antisense Oligonucleotide Therapies market will register a % CAGR in terms of revenue, the global market size will reach US$ million by 2026.

This report presents a comprehensive overview, market shares, and growth opportunities of Antisense Oligonucleotide Therapies market by product type, application, key players and key regions and countries.

Segmentation by type: breakdown data from 2016 to 2021 in Section 2.3; and forecast to 2026 in section 10.7.
Without GalNAc-conjugated
With GalNAc-conjugated

Segmentation by application: breakdown data from 2016 to 2021, in Section 2.4; and forecast to 2026 in section 10.8.
Genetic Disease
Cancer
Cardiovascular Diseases
Other

This report also splits the market by region: Breakdown data in Chapter 4, 5, 6, 7 and 8.
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries

The report also presents the market competition landscape and a corresponding detailed analysis of the major players in the market. The key players covered in this report: Breakdown data in in Chapter 3.
Ionis Pharmaceuticals
Sarepta Therapeutics
Nippon Shinyaku
Buy now